GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.

GeneDx Holdings Corp. Class A Common Stock

GeneDx is focused on delivering personalized, actionable insights that improve health outcomes. We sit at the intersection of diagnostics and data science, pairing decades of genomic expertise with an unmatched ability to interpret clinical data at scale.

Our exome and genome testing is among the best in the industry. We expect that it will be even more advanced in the future with the help of Centrellis®, our innovative health information platform. Powered by millions of medical records, Centrellis® integrates digital tools with artificial intelligence to ingest and synthesize clinical and genomic data.

As a result of our robust test menu, including our exome and genome testing, and the comprehensive insights generated by Centrellis®, we are developing a more complete understanding of complex disease than ever before. This translates to faster diagnosis, more effective treatment plans, and enhanced drug discovery.

Our offerings help a whole spectrum of healthcare partners -- clinicians, researchers, health systems, pharmaceutical companies, and payors -- improve patient experiences and advance population health.

GeneDx

Congratulations to Akouos on the news of their investigational #gene therapy treatment for otoferlin gene (OTOF)-mediated hearing loss, a rare congenital deafness impacting roughly 200,000 people worldwide. GeneDx is proud to partner with Akouos to help accelerate enrollment in #clinicaltrials by leveraging our robust dataset to identify other #patients who can benefit from these #therapies. We’re humbled to be part of the ecosystem of #healthcare innovation and improving access to pioneering treatments for more patients. 

https://nyti.ms/3OlRYAK

9 state #Medicaid programs now cover rapid whole #genome #sequencing (rWGS) in the #pediatric inpatient setting.  

Utah joins a growing list of states who recognize the importance of offering rWGS in the #NICU and PICU to provide a rapid #diagnosis for the most vulnerable patients and their families.

Couldn’t be prouder of the entire team at GeneDx on an outstanding fourth quarter. Our preliminary results put us ahead on revenue and cash burn goals. We’re proving that we can work together as a team committed to our patients, our providers, our partners, and to our shareholders. 2024 is already off to a strong start. Thank you to everyone for helping keep our eyes on the goal of diagnosing inherited disease earlier, connecting people with the right treatment, and driving a healthier future for as many families as possible.
https://lnkd.in/eHQUhcK8

Harness deep #genomic data. Provide more definitive #answers. Deliver improved outcomes. With one of the world’s largest #raredisease clinical data sets, GeneDx can help you bring #precision medicine into your practice. Our vision is big: leverage tomorrow’s technology to improve patients’ lives, today.

Uncertainty and delayed diagnoses are too common among patients with #neurodevelopmental disorders (NDDs). That’s why leading medical societies recognize #exome or #genome #sequencing as the best, first-tier #genetic testing option. 

For a child with NDDs, every day without a genetic #diagnosis is a missed opportunity. With GeneDx exome testing, you can provide more timely, cost-effective, and comprehensive clinical evaluations that deliver actionable insights. 

Choose a comprehensive and cost-effective genetic testing option supported by leading medical societies.

There’s no place like home for the #holidays. But for the most vulnerable #patients and their families, this isn’t always a possibility. Give them the gift of #genetic insights that can help inform #diagnosis, direct #treatment, and make sure they’re back where they belong: in the arms of their loved ones.

Five. That’s how many uninformative tests the average child with #neurodevelopmental disorders undergoes in search of a #genetic diagnosis. Find critical information sooner by ordering GeneDx #exome first. Test once, discover more, and help your #patients get the care they need #earlier.

Incorporating comprehensive #genomic #sequencing into your workflow doesn’t have to be complicated. Instead, let us do the heavy lifting. We can assist with: 
✅ selecting appropriate tests 
✅ answering #clinical questions 
✅ reporting patient-centric #results 
✅ guiding potential next steps 
 
With comprehensive care from start to finish, GeneDx offers more than a test result: we deliver actionable insights that promote optimal #health.

Are you a #healthcare provider working in a #NICU? Do you want to implement rapid #GeneticTesting, but lack genetic specialist support?

Learn how to interpret #genetic results & discuss them with caregivers, with insights from a panel of experts. 

Click here, watch at your convenience & earn 1 #CME credit 👉 https://bit.ly/47lLd9N

What more can you do for your patients in the #NICU? Rapid whole #genome sequencing (rWGS) might be the answer. It’s been shown to: 
✅ Change clinical management in 61% of patients 
✅ Reduce the length of NICU stays by >457 days 
✅ Reduce #healthcare costs by $12K-16K per #patient 
 
Learn more about the power of #rWGS by visiting the GeneDx team at the Nemours Children's #Neonatology Conference in Oxon Hill, MD. We look forward to seeing you!

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
average inventory			29.21M -	23.56M 19.34%	11.22M 52.37%
average payables			35.72M -	45.35M 26.99%	41.74M 7.98%
average receivables			29.45M -	34.95M 18.69%	38.08M 8.94%
book value per share		-45.35 -	118.50 361.33%	2.35 98.02%	9.38 299.53%
capex per share	-2.12 -	-4.39 106.87%	-6.35 44.48%	-0.13 97.91%	-0.23 77.27%
capex to depreciation	-2.41 -	-2.72 12.96%	-0.95 65.02%	-0.24 74.67%	-0.17 29.89%
capex to operating cash flow	0.83 -	0.34 58.40%	0.11 68.21%	0.04 58.89%	0.03 29.78%
capex to revenue	-0.08 -	-0.18 126.31%	-0.10 45.06%	-0.06 37.70%	-0.03 53.80%
cash per share		14.86 -	122.31 723.27%	1.15 99.06%	5.35 366.84%
days of inventory on hand		51.98 -	53.37 2.69%	19.08 64.26%	22.59 18.42%
days payables outstanding		55.67 -	71.30 28.07%	64.24 9.89%	96.41 50.07%
days sales outstanding		65.81 -	45.69 30.57%	67.41 47.52%	59.13 12.28%
debt to assets		0.18 -	0.06 66.87%	0.15 148.72%	0.13 8.76%
debt to equity		-0.14 -	0.08 162.04%	0.29 237.11%	0.25 13.40%
dividend yield
earnings yield	-0.01 -	-0.09 605.87%	-0.51 447.78%	-0.58 14.56%	-2.63 350.80%
enterprise value		2.59B -	114.30M 95.58%	889.81M 678.47%	86.45M 90.28%
enterprise value over ebitda		-11.40 -	-0.27 97.64%	-2.25 735.03%	-0.70 68.68%
ev to operating cash flow		-27.80 -	-0.60 97.84%	-2.79 364.50%	-0.48 82.89%
ev to sales		14.44 -	0.54 96.27%	3.79 603.84%	0.43 88.74%
free cash flow per share	-4.70 -	-17.19 265.97%	-64.49 275.22%	-3.09 95.22%	-7.69 149.22%
free cash flow yield	-0.01 -	-0.05 224.86%	-0.44 828.81%	-0.35 19.16%	-2.80 689.36%
graham net net		-60.02 -	82.82 237.99%	-0.68 100.83%	-1.30 89.86%
graham number		185.86 -	446.96 140.48%	16.38 96.34%	39.06 138.46%
income quality	0.63 -	0.39 38.80%	0.78 101.11%	0.58 25.09%	1.03 77.37%
intangibles to total assets	0 -	0	0	0.38 Infinity%	0 100%
interest coverage	-38.84 -	-97.81 151.83%	-157.37 60.89%	-208.19 32.29%
interest debt per share		6.53 -	10.89 66.94%	0.70 93.58%	2.32 231.30%
inventory turnover		7.02 -	6.84 2.62%	19.13 179.76%	16.16 15.55%
invested capital		-0.14 -	0.08 162.04%	0.29 237.11%	0.25 13.40%
market cap	2.35B -	2.65B 12.65%	482.03M 81.82%	941.35M 95.29%	66.86M 92.90%
net current asset value		-407.58M -	317.55M 177.91%	-24.61M 107.75%	-8.40M 65.87%
net debt to ebitda		0.28 -	0.87 211.89%	0.13 84.96%	-0.16 222.53%
net income per share	-4.26 -	-33.86 695.19%	-74.93 121.30%	-5.08 93.22%	-7.23 42.33%
operating cash flow per share	-2.57 -	-12.79 397.27%	-58.15 354.45%	-2.95 94.92%	-7.45 152.45%
payables turnover		6.56 -	5.12 21.92%	5.68 10.98%	3.79 33.36%
receivables turnover		5.55 -	7.99 44.04%	5.41 32.21%	6.17 14.00%
research and ddevelopement to revenue	0.18 -	0.41 127.82%	0.50 22.24%	0.37 25.89%	0.24 34.98%
return on tangible assets		-0.98 -	-0.44 54.78%	-1.80 307.37%	-0.42 76.73%
revenue per share	26.95 -	24.64 8.59%	64.79 162.98%	2.17 96.65%	8.33 283.69%
roe		0.75 -	-0.63 184.68%	-2.16 242.23%	-0.77 64.38%
roic		0.95 -	-1.01 206.32%	-1.56 55.09%	-0.45 71.32%
sales general and administrative to revenue	0.15 -	0.56 273.79%	0.97 72.79%	0.87 10.75%
shareholders equity per share		-45.35 -	118.50 361.33%	2.35 98.02%	9.38 299.53%
stock based compensation to revenue	0.03 -	0.67 2,299.30%	1.03 54.23%	0.18 82.70%	-0.51 384.81%
tangible asset value		-330.05M -	388.10M 217.59%	67.06M 82.72%	228.02M 240.04%
tangible book value per share		-45.35 -	118.50 361.33%	0.62 99.48%	9.38 1,411.65%
working capital		100.67M -	382.26M 279.73%	68.33M 82.13%	123.52M 80.78%

COM:GENEDX

GeneDx Holdings Corp.

Last Close

72.07

22/11 21:00

Market Cap

2.16B

Beta: -

Volume Today

549.30K

Avg: -

Preview